RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”), today announced that, as part of the ongoing evolution of its corporate strategy, it has retained Farris LLP as its legal counsel and Dale Matheson Carr-Hilton Labonte LLP as its auditors.

RavenQuest CEO, George Robinson, stated, “from a cannabis perspective, both Farris LLP and Dale Matheson Carr-Hilton Labonte LLP bring the experience, perspective and expertise we are looking for in our legal and auditing teams. In keeping with our ongoing theme of adding advisors with a deep level of knowledge in the cannabis space, we are very excited to bring both groups onboard in their respective advisory capacities.”

For more information, access RavenQuest’s investor presentation, fact sheet and videos here.

Follow RavenQuest:TwitterInstagramFacebookLinkedIn

About RavenQuest BioMed Inc.

RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company also focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors ofRAVENQUEST BIOMED INC.

“George Robinson”Chief Executive Officer

For further information, please contact: Mathieu McDonald, Corporate Communications1-877-282-1586

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

RavenQuest BioMed (CSE:RQB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse RavenQuest BioMed
RavenQuest BioMed (CSE:RQB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse RavenQuest BioMed